Haemonetics (NYSE: HAE) reported Q3 EPS of $0.62, which may note compare to the analyst estimate of $0.44. Revenue for the quarter came in at $234 million versus the consensus estimate of $227.67 million.

Chris Simon, Haemonetics’ CEO, stated: “Our strategy is working and we have good momentum in our businesses, including revenue mix, gross margin and net income. The Company moved forward with the Complexity Reduction Initiative and the turnaround is on track. We are raising our fiscal 2018 adjusted earnings per share and free cash flow guidance.”

The Company announced that its Board of Directors has authorized the repurchase of up to $260 million of Haemonetics common shares through March 30, 2019.

For earnings history and earnings-related data on Haemonetics (HAE) click here.